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Abstract
Background: Natural products are well recognized as sources of drugs in several human ailments. In the present work, we
carried out a preliminary screening of six natural compounds, xanthone V1 (1); 2-acetylfuro-1,4-naphthoquinone (2);
physcion (3); bisvismiaquinone (4); vismiaquinone (5); 1,8-dihydroxy-3-geranyloxy-6-methylanthraquinone (6) against
MiaPaCa-2 pancreatic and CCRF-CEM leukemia cells and their multidrug-resistant subline, CEM/ADR5000. Compounds 1 and
2 were then tested in several other cancer cells and their possible mode of action were investigated.
Methodology/Findings: The tested compounds were previously isolated from the Cameroonian medicinal plants Vismia
laurentii (1, 3, 4, 5 and 6) and Newbouldia laevis (2). The preliminary cytotoxicity results allowed the selection of xanthone V1
and 2-acetylfuro-1,4-naphthoquinone, which were then tested on a panel of cancer cell lines. The study was also extended
to the analysis of cell cycle distribution, apoptosis induction, caspase 3/7 activation and the anti-angiogenic properties of
xanthone V1 and 2-acetylfuro-1,4-naphthoquinone. IC50 values around or below 4 mg/ml were obtained on 64.29% and
78.57% of the tested cancer cell lines for xanthone V1 and 2-acetylfuro-1,4-naphthoquinone, respectively. The most sensitive
cell lines (IC50,1 mg/ml) were breast MCF-7 (to xanthone V1), cervix HeLa and Caski (to xanthone V1 and 2-acetylfuro-1,4-
naphthoquinone), leukemia PF-382 and melanoma colo-38 (to 2-acetylfuro-1,4-naphthoquinone). The two compounds
showed respectively, 65.8% and 59.6% inhibition of the growth of blood capillaries on the chorioallantoic membrane of
quail eggs in the anti-angiogenic assay. Upon treatment with two fold IC50 and after 72 h, the two compounds induced cell
cycle arrest in S-phase, and also significant apoptosis in CCRF-CEM leukemia cells. Caspase 3/7 was activated by xanthone
V1.
Conclusions/Significance: The overall results of the present study provided evidence for the cytotoxicity of compounds
xanthone V1 and 2-acetylfuro-1,4-naphthoquinone, and bring supportive data for future investigations that will lead to their
use in cancer therapy.
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Introduction
Natural products are well recognized as sources for drugs in
several human ailments including cancers. Examples of natural
pharmaceuticals from plants include vincristine, irinotecan,
etoposide and paclitaxel [1]. Despite the discovery of many drugs
of natural origin, the search for new anticancer agents is still
necessary, in order to increase the range available and to find less
toxic and more effective drugs. It has been recommended that
samples with pharmacological usage should be taken into account
when selecting plants to treat cancer, as several ailments reflect
disease states bearing relevance to cancer or cancer-like symptoms
[2,3]. Therefore, we designed the present work to investigate the
cytotoxicity of six natural compounds available in our research
group, with previously demonstrated pharmacological activities.
Compound 1 has been isolated from the roots of Cratoxylum
formosum [4], the leaves of Symphonia globulifera [5], and the seeds of
Vismia laurentii [6]. The only reported natural source of compound
2 is Newbouldia laevis in which it can be isolated from the roots [7].
Compound 3 is a key active ingredient of the ethanol extract from
roots of Chinese rhubarb (Rheum officinale Baill.) that has been
commercialised in China for controlling powdery mildews [8].
Compound 3 was purified from several plants including Rumex
japonicus [9], Radix Boehmeriae [10], Discocleidion rufescens [11], Senna
septemtrionalis [12], etc. Compounds 4 and 5 are mostly found in
plants of the genus Vismia [13,14], whilst compound 6 was
reported in Vimia laurentii [13] and Psorospermum species [15].
Compounds 2; 4; 5 and 6 previously showed antimicrobial
activities against a panel of bacteria and fungi [13,16]; compound
3 exhibited antibacterial activities against Chlorella fusa and Bacillus
megaterium, respectively [6] and compound 1 showed antileishma-
nial [5] and cytotoxic activities against HeLa, HT-29 and KB cell
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activities on Pseudomonas aeruginosa, Bacillus cereus, Staphylococcus
aureus, Streptococcus faecalis and Salmonella typhi with minimal
inhibitory concentration below 10 mg/ml [4]. In the present work,
we examined at first, the cytotoxicity of compounds 1–6 against
MiaPaCa-2, CCRF-CEM, and CEM/ADR5000 cell lines, then
we selected compounds 1 and 2 which were tested on a panel of
cancer cells. Their possible modes of action were also investigated
and reported herein.
Results and Discussion
The six naturally occuring compounds tested included one
xanthone named xanthone V1 (1) and five quinones amongst
which were three anthraquinones known as physcion (3);
vismiaquinone (5) and 1,8-dihydroxy-3-geranyloxy-6-methylan-
thraquinone (6), one naphthoquinone known as 2-acetylfuro-1,4-
naphthoquinone (2) and one binaphthoquinone named bisvismia-
quinone (4) (Fig. 1). The four studied naphtoquinones have
compound 3 as the basic moiety. The preliminary cytotoxicity of
the six studied compounds on CCRF-CEM, CEM/ADR5000 and
MiaPaca-2 is summarized in Fig. 2. Only xanthone V1 and 2-
acetylfuro-1,4-naphthoquinone as well as doxorubicin were able to
reduce the proliferation of the three cell lines by up to 50%, when
tested at 20 mg/ml. Physcion was previously found to have no
cytotoxic activity on some cancer cell lines such as K562, HeLa,
Calu-1, Wish and Raji [17] and was not significantly active as
observed in the present work. However, the low activity of 8-
dihydroxy-3-geranyloxy-6-methylanthraquinone (6), as well as
bisvismiaquinone (4) and vismiaquinone (5) also bearing physcion
(3) moiety, clearly highlights the low cytotoxicity of the studied
anthraquinones. It can be deduced that the best cytotoxic activity
of the studied compounds were obtained with the tested xanthone
(xanthone V1) and naphthoquinone (2-acetylfuro-1,4-naphthoqui-
none). Xanthone V1 and 2-acetylfuro-1,4-naphthoquinone were
therefore selected and tested on several cancer cells. The IC50
values obtained are reported in Table 1 and values below 20 mg/
ml were recorded on 12 of the 14 (85.71%) tested cancer cell lines
for xanthone V1 and 14/14 (100%) for 2-acetylfuro-1,4-naphtho-
quinone. Considering the cut-off points of 4 mg/ml [18] or 10 mM
[19] for good cytotoxic compounds, values around or below this
set point were obtained by xanthone V1 on 9/14 (64.29%) tested
cancer cell lines and 11/14 (78.57%) for 2-acetylfuro-1,4-
naphthoquinone. The most sensitive cell lines (with IC50 values
below 1 mg/ml) were breast MCF-7 (to xanthone V1) and cervix
HeLa and Caski (to xanthone V1 and 2-acetylfuro-1,4-naphtho-
quinone), leukemia PF-382 and melanoma colo-38 (to 2-
acetylfuro-1,4-naphthoquinone). The liver is the main organ
involved in drug metabolism. Therefore AML12 hepatocyte were
choosen in the present work to evaluate the cytotoxicity of the
compounds on non cancer cells. Interrestingly, the two com-
pounds were generally less toxic on AML12 cells, the IC50 being
above 20 mg/ml. In addition, the two compounds showed
respectively, 65.8% and 59.6% inhibition of the growth of blood
capillaries on the chorioallantoic membrane of quail eggs in the
anti-angiogenic assay (Fig. 3), suggesting that negative effect on
tumor promotion in vivo could be expected. To the best of our
knowledge, the anticancer activity of 2-acetylfuro-1,4-naphthoqui-
none is being reported herein for the first time meanwhile the
cytotoxicity of xanthone V1 was reported on HeLa, HT-29 and
KB cell lines [4]. This study thus confirms the cytotoxic potency of
xanthone V1 on a large number of cancer cell lines. The effects on
xanthone V1 and 2-acetylfuro-1,4-naphthoquinone on the cell
cycle distribution, apoptosis induction (Figs. 4 and 5) and caspase
3/7 activity (Fig. 6) were investigated in CCRF-CEM cell line.
Fig. 4 shows that xanthone V1 was able to induce cell cycle arrest
at higher concentration (26IC50). At 26IC50, the cell number in
S-phase gradually increased (Fig. 4B1–3) with time upon treatment
with xanthone V1, and the highest amount was observed after
72 h, suggesting a cycle arrest at this phase. Up to 8.51% and
10.53% apoptotic cells were observed after 72 h upon treatemnt of
CCRF-CEM cells with xanthone V1 at IC50 and 26IC50,
respectively. This result is in accordance with the activation of
caspases 3/7 (182.58% activation compare to untreated cells)
(Fig. 6), though the effect at 26IC50 was less than that obtained at
a concentration corresponding to IC50 value (1231% activation).
This is obviously due to the fact that, despite the activation of
caspase induced by this compound, the ratio of cell number-
activity might still be better at IC50 than at 26IC50. Fig. 5 also
shows that 2-acetylfuro-1,4-naphthoquinone induced cell cycle
arrest in S-phase when tested at 26IC50 and IC50 values in a time-
dependant manner. This compound induced apoptosis,
eventhough without caspase 3/7 activation (data not shown). This
suggests that the activation of caspase might not be the main
pathway for apoptosis induction by 2-acetylfuro-1,4-naphthoqui-
none.
The overall results of the present work highlight the anticancer
potency of xanthone V1 and 2-acetylfuro-1,4-naphthoquinone,
and clearly justify the fact that all compounds with any
pharmacological activity should also be evaluated for its
cytotoxicity. The most sensitive cancer cell lines to xanthone V1
and 2-acetylfuro-1,4-naphthoquinone were Colo-38 (melanoma),
HeLa and Caski (cervix cancer) with IC50 values being closer or
lower those obtained with doxorubicin. In addition, MCF-7
(breast cancer) and PF-382 (leukemia) also showed high sensitivity
to xanthone V1 and 2-acetylfuro-1,4-naphthoquinone respectively.
The cytotoxicity of acetylfuro-1,4-naphthoquinone is being
reported for the first time. Regarding the medical impact of these
cancers, the activities of these two molecules could be considered
as very important. In fact, breast cancer is the most frequently
diagnosed cancer and the leading cause of cancer death among
females worldwide, accounting for 23% of the total cancer cases
and 14% of the cancer deaths, meanwhile cervix and colon
cancers are also amongst the most common cancer in econom-
ically developing and developped world respectively [20].
In conclusion, the results of the present study provide evidence
of the cytotoxicity of xanthone V1 and 2-acetylfuro-1,4-naphtho-
quinone, and bring supportive data for future investigations that
will lead to their use in cancer therapy.
Materials and Methods
Ethics Statement
Cell lines were obtained from different sources; Prof. Axel
Sauerbrey, University of Jena, Jena, Germany: CCRF-CEM,
CEM/ADR5000, HL-60; German Collection for Microorganisms
and Cell Culture (DSMZ), Braunschweig, Germany: PF-382; Dr.
Jo ¨rg Hoheisel, DKFZ, Heidelberg, Germany: MiaPaCa-2, Capan-
1 pancreatic adenocarninoma, MCF-7 breast adenocarcinoma,
SW-680 colon carcinoma cells; Tumor Bank, German Cancer
Research Center (DKFZ), Heidelberg, Germany: 786-0 renal
carcinoma cells, U87MG glioblastoma-astrocytoma cells, A549
lung adenocarcinoma, Caski and HeLa cervical carcinoma cells,
Colo-38 skin melanoma cells; ATCC, USA: AML12 hepatocytes.
Chemical for cytotoxicity assay
Doxorubicin (Sigma-Aldrich, Schnelldorf, Germany) was used
as a positive (cytotoxic) control. The six natural compounds tested
Anticancer Activities of Natural Compounds
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as well as characterization were previously reported: xanthone V1
C23H22O6 (1; m/z 394; m.p. 214–215, yellow powder) and
physcion C16H12O5 (3; m/z 394; m.p. 202–205, orange solid)
from the seeds of Vismia laurentii [6]; 2-acetylfuro-1,4-naphthoqui-
none C14H8O4 (2; m/z: 242; m.p. 224–225; yellow powder) from
the roots bark of Newbouldia laevis [21]; bisvismiaquinone
C12H42O8 (4; m/z: 674; m.p. 207–209; yelow powder), vismia-
quinone C21H20O5 (5; m/z: 352; m.p. 201–203; red powder), 1,8-
dihydroxy-3-geranyloxy-6-methylanthraquinone C25H26O5 (6;
m/z: 406; m.p. 119–121; orange needle) from the twigs of Vismia
laurentii [13]. The determination of each chemical structure was
made as previously reported [6,21,13]. Generally they were
determined on the basis of spectral data produced by one- and
two-dimensional nuclear magnetic resonance (NMR), recorded on
Bru ¨ker DRX-400 instrument. This spectrometer was equipped
with 5 mm,
1H and
13C NMR probes operating at 400 and
100 MHz, with tetramethylsilane as internal standard. Mass
spectra were recorded on an API QSTAR pulsar mass
spectrometer. All chemicals were stored at 4uC before use.
Figure 1. Chemical structures of the studied compounds. 1: xanthone V1, 2: 2-acetylfuro-1,4-naphthoquinone; 3: physcion; 4:
bisvismiaquinone; 5: vismiaquinone; 6: 1,8-dihydroxy-3-geranyloxy-6-methylanthraquinone.
doi:10.1371/journal.pone.0021762.g001
Figure 2. Growth percentage (%) of compounds and doxorubicin tested at 20 mg/ml on CCRF-CEM, CEM/ADR5000 and MiaPaCa-2
cell lines. 1: xanthone V1, 2: 2-acetylfuro-1,4-naphthoquinone; 3: physcion; 4: bisvismiaquinone; 5: vismiaquinone; 6: 1,8-dihydroxy-3-geranyloxy-6-
methylanthraquinone. Data with different superscript letters are significantly different (P,0.05).
doi:10.1371/journal.pone.0021762.g002
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A panel of fourteen cancer cell lines including human CCRF-
CEM leukemia cells and their multidrug-resistant subline, CEM/
ADR5000, PF-382 leukemia T-cells, and HL-60 promyelocytic
leukemia (moderately differentiated), MiaPaCa-2 and Capan-
1pancreatic adenocarninoma, MCF-7 breast adenocarcinoma,
SW-680 colon carcinoma cells, 786-0 renal carcinoma cells,
U87MG glioblastoma-astrocytoma cells, A549 lung adenocarci-
noma, Caski and HeLa cervical carcinoma cells, Colo-38 skin
melanoma cells, as well as AML12 hepatocytes (poorly differen-
tiated), were used. CCRF-CEM, CEM/ADR5000 and MiaPaCa-
2 cells were used for the preliminary assay and the most actives
compounds were tested on other cell lines. Leukemia cells were
maintained in RPMI 1640 containing 100 units/ml penicillin and
100 mg/ml streptomycin and supplemented with heat-inactivated
10% fetal bovine serum (FBS). All cultured cells were maintained
in a humidified environment at 37uC with 5% CO2. Doxorubicin
(Sigma-Aldrich, Schnelldorf, Germany) was used as a positive
(cytotoxic) control. The concentration of DMSO was not greater
than 0.1% in all experiments.
Resazurin cell growth inhibition assay
Alamar Blue or Resazurin (Promega, Mannheim, Germany)
reduction assay [22] was used to assess the cytotoxicity of the
studied samples. The assay tests cellular viability and mitochon-
drial function. Briefly, adherent cells were grown in tissue culture
flasks, and then harvested by treating the flasks with 0.025%
trypsin and 0.25 mM EDTA for 5 min. Once detached, cells were
washed, counted and an aliquot (5610
3 ells) was placed in each
well of a 96-well cell culture plate in a total volume of 100 ml. Cells
were allowed to attach overnight and then treated with samples.
The final concentration of samples ranged from 20-0.16 mg/ml.
After 48 h, 20 ml resazurin 0.01% w/v solution was added to
each well and the plates were incubated at 37uC for 1–2 h.
Table 1. Cytotoxicity of compounds 1, 2 and doxorubicin on different cancer cell lines.
Cell lines Samples and IC50 values
1 2 Doxorubicin
mg/ml mM mg/ml mM mg/ml mM
CCRF-CEM 4.9060.71 12.4461.80 9.4162.79 35.88611.53 1.24±0.003 1.2860.005
CEM/ADR5000 19.0662.21 48.0765.61 16.7560.42 69.2161.74 .20 .36.8
PF-382 .20 .50.76 0.57±0.06 2.3660.25 1.9060.037 3.5060.007
HL-60 4.5660.57 11.5761.42 4.8160.77 19.8863.18 1.5760.11 2.8960.20
MiaPaCa-2 18.5661.76 47.1164.47 1.8160.02 7.4860.08 0.95±0.06 1.7560.11
Capan-1 .20 .50.76 3.8160.96 15.7463.97 4.0661.18 7.4762.17
MCF-7 0.56±0.06 1.4260.15 1.6660.09 6.8660.72 0.59±0.05 1.0860.09
SW-680 8.4060.45 21.3261.14 3.5560.02 14.6760.08 0.93±0.09 1.7160.17
786-0 3.7960.16 9.6260.41 6.8160.61 28.1462.52 0.60±0.09 1.1060.17
U87MG 3.8060.01 9.6460.03 1.9460.18 8.0260.74 0.37±0.08 0.6860.14
A549 3.9960.09 10.1360.23 5.4960.35 22.6961.44 1.6960.05 3.1160.09
Colo-38 1.19±0.07 3.0261.78 0.67±0.18 2.7760.74 0.81±0.06 1.4960.11
HeLa 0.23±0.01 0.5860.03 0.40±0.10 1.6560.41 0.26±0.02 0.4860.04
Caski 0.24±0.01 0.6160.03 0.17±0.03 0.7060.12 0.58±0.02 1.0760.04
AML12 (EC50)* .20 .50.76 .20 .82.64 .20 .36.8
*EC50: effective dose showing 50% inhibition of growth proliferation.
doi:10.1371/journal.pone.0021762.t001
Figure 3. Effects of compound 1 and 2 (at 20 mg/ml) on the growth of blood capillaries on the chorioallantoic membrane of quail
eggs. (A) DMSO (Control): growth of blood capillaries on the CAM – no antiangiogenic effect; (B): compound 1 (65.8% inhibition); (C): compound 2
(59.6% inhibition). Quantitative analysis was performed using a software routine which was written in the Image J-macro language, and the total
small vessels number was then determined by the system as 44644 (control), 15273 (compound 1) and 18050 (compound 2). The inhibition
percentage was then calculated as previously described [27].
doi:10.1371/journal.pone.0021762.g003
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M2000 Pro
TM plate reader (Tecan, Crailsheim, Germany) using
an excitation wavelength of 544 nm and an emission wavelength
of 590 nm. For leukemia cells, aliquot of 5610
4 cells/ml (obtained
from overnight suspension) were seeded in 96-well plates, and
extracts were added immediately. After 24 h incubation, plates
were treated with resazurin solution as above mentioned.
Doxorubicin was used as positive control. Each assay was done
at least three times, with two replicates each. The viability was
compared based on a comparison with untreated cells. IC50 (on
cancer cells) or EC50 (on AML12 cells) values were the
concentration of sample required to inhibit 50% of the cell
proliferation and were calculated from a calibration curve by a
linear regression [23] using Microsoft Excel.
Flow cytometry for cell cycle analysis and detection of
apoptotic cells
Leukemia CCRF-CEM cells treated with compounds 1 and 2
or DMSO (solvent control) for 24 to 72 h were fixed with ethanol
95% and washed with cold, phosphate-buffered saline (PBS;
Invitrogen) and then resuspended in 150 ml hypotonic fluoro-
chrome solution (50 mg/ml propidium iodide, 0.1% (w/v) sodium
citrate and 0.1% (v/v) Triton X-100). The cells were incubated in
the dark at 4uC overnight before flow-cytometry analysis was
performed. The propidium iodide fluorescence of individual nuclei
was measured using a FACS-Calibur cytometer (BD Biosciences,
Heidelberg, Germany). Data were analyzed with the CellQuess
Pro V5.2.1 software (BD Biosciences). For each condition, at least
three independent experiments were performed.
Caspase-Glo 3/7 assay
The influence of compounds 1 and 2 on caspase 3/7 activity in
CCRF-CEM leukemia cell line was detected using Caspase-Glo 3/
7 Assay kit (Promega). Cells cultured in RPMI were seeded in 96-
well plates and treated with the sample (26IC50;I C 50; K IC50)o r
DMSO (solvent control). After 24 h treatment, 100 ml of caspase
3/7 reagent were added to each well, mixed and incubated for 1 h
at room temperature. Luminescence was measured using well
Infinite M2000 Pro
TM instrument (Tecan). Caspase 3/7 activity
was expressed as percentage of the untreated control.
Angiogenesis test
Cultivation of quail eggs. The quail eggs were purchased
from Wachtelzucht Anne Klein, Steinhagen, Germany.
The embryos were cultured according to the method described
by Wittmann et al. [24]. Briefly, fertilized quail eggs were
incubated for 70 h at 38uC and 80% relative humidity. After 70 h
of incubation the eggs were opened. For this purpose, the eggs
were placed in a vertical position to guarantee that the embryo
floats in the upper part of the egg. Afterwards, hole was cut in to
the top of the egg and the complete content of the egg was
transferred into a Petri dish. By using this method, it could be
Figure 4. Cell cycle distribution with Leukemia CCRF-CEM treated with compounds 1. A1: control after 24 h; A2: control after 48 h; A3:
control after 72 h; B1: treated with 26IC50 after 24 h; B2: treated with 26IC50 after 48 h; B3: treated with 26IC50 after 72 h; C1: treated with 26IC50
after 24 h; C2: treated with 26IC50 after 48 h; C3: treated with 26IC50 after 72 h; D1: treated with 26IC50 after 24 h; D2: treated with 26IC50 after
48 h; D3: treated with 26IC50 after 72 h.
doi:10.1371/journal.pone.0021762.g004
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by the yolk with the embryo on top without exposing the embryo
to shock-forces which could damage the vitelline membrane.
Chicken-Chorioallantoic-membran-Assay (CAM-Assay)
Compounds 1 and 2 were tested for their anti-angiogenic effects
using the method of D’Arcy and Howard [25], with modifications
Figure 5. Cell cycle distribution with Leukemia CCRF-CEM treated with compounds 2. A1: control after 24 h; A2: control after 48 h; A3:
control after 72 h; B1: treated with 26IC50 after 24 h; B2: treated with 26IC50 after 48 h; B3: treated with 26IC50 after 72 h; C1: treated with 26IC50
after 24 h; C2: treated with 26IC50 after 48 h; C3: treated with 26IC50 after 72 h; D1: treated with 26IC50 after 24 h; D2: treated with 26IC50 after
48 h; D3: treated with 26IC50 after 72 h.
doi:10.1371/journal.pone.0021762.g005
Figure 6. Enzymatic activity of caspase 3/7 after 6 h treatment of CCRF-CEM cells with compounds 1. The activity of caspase 3/7 is
expressed as percentage % relative to untreated cells. Compound 2 did not show any induction of caspase 3/7 activity (data not shown). Values are
mean 6 SD of three duplicated experiments.
doi:10.1371/journal.pone.0021762.g006
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was placed in an incubator for 2 h at 38uC to acclimatize to the
new ambience. Subsequently, the test substance was placed on the
chorioallantoic membrane (CAM). Therefore, 2% agarose solu-
tion was prepared and mixed 1:10 with compounds prior diluted
in DMSO 0.1% final concentration. The final concentration of the
substance was 20 mg/ml. Pellets with 0.1% DMSO served as
control. The agarose-pellets were then placed on the chorioallan-
toic membrane after they cooled down to room temperature. The
Petri dishes with the quail embryos were placed in the incubator
again and incubated at 38uC and 80% relative humidity for 24 h
before documenting the effect of the applied substance.
Imaging of the vascularized quail eggs was performed using a
digital camera with 36-magnification objective (Canon eos 500
with a canon mp-e 65 2.8 macro objective). For illumination, a
mercury-arc-lamp was used which provided a high fraction of blue
and UV-light to obtain good contrast values between yolk and
vessels. The pictured image section had a size of 565 mm.
Following image acquisition, quantitative analysis was performed
using a software routine which was written in the Image J-macro
language, and the total small vessels number (or area) was then
determined by the system. The percentage inhibition of vascular-
ization was calculated as previously described [27].
Statistical analysis
Statistical analysis of all data was performed using a Student’s t-
test or Kruskal–Wallis test followed by Dunn’s post-hoc multiple
comparison test (Graph-Pad Prism 5.01; GraphPad Software, Inc.,
CA, USA). P,0.05 denoted significance in all cases.
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